Perspective on the risks of infection and malignancy with rheumatoid arthritis therapy

By Hudson Marie   Suissa Samy  

Future Rheumatology, Vol. 3, Iss. 5, 2008-10 ,pp. : 445-449

Future Medicine

Access to resources Recommend Favorite

Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate

By Fitzpatrick Ray   Scott David   Keary Ian  

Clinical Rheumatology, Vol. 32, Iss. 11, 2013-11 ,pp. : 1605-1612

Springer Publishing Company

Access to resources Recommend Favorite

Update on Targets of Biologic Therapies for Rheumatoid Arthritis

By  

Current Rheumatology Reviews, Vol. 4, Iss. 4, 2008-11 ,pp. : 246-253

Bentham Science Publishers

Access to resources Recommend Favorite

Depression is improved when low-dose tacrolimus is given to rheumatoid arthritis patients showing an inadequate response to biologic agents

By Miwa Yusuke   Hosaka Michio   Ohtsuka Kumiko   Sato Michihito   Takahashi Ryo   Wakabayashi Kuninobu   Odai Tsuyoshi   Yajima Nobuyuki   Kasama Tsuyoshi  

Modern Rheumatology, Vol. 23, Iss. 5, 2013-09 ,pp. : 920-924

Springer Publishing Company

Access to resources Recommend Favorite

Distribution of Podoplanin in Synovial Tissues in Rheumatoid Arthritis Patients Using Biologic or Conventional Disease-Modifying Anti-Rheumatic Drugs

By  

Current Rheumatology Reviews, Vol. 13, Iss. 1, 2017-01 ,pp. : 72-78

Bentham Science Publishers

Access to resources Recommend Favorite